Tag: filing

RACINE, Wis., June 26, 2025 (GLOBE NEWSWIRE) -- Johnson Outdoors Inc. (Nasdaq: JOUT), a leading global innovator of outdoor recreation equipment and technology, today announced approval by its Board of Directors of a quarterly cash dividend of $0.33 per Class A share and $0.30 per Class B share.

CALGARY, ALBERTA, June 26, 2025 (GLOBE NEWSWIRE) -- Marksmen Energy Inc. ("Marksmen" or the "Company") is providing this announcement further to its news releases dated May 15 and 29, June 12 and 16, 2025, with respect to the Alberta Securities Commission ("ASC") having issued a management cease trade order ("MCTO") to Marksmen pursuant to its application under National Policy 12-203 Management Cease Trade Orders ("NP 12-203") in respect of the default regarding the delay of the filing of its annual financial statements, accompanying management’s discussion and analysis and related chief executive officer ("CEO") and chief financial officer ("CFO") certifications for the financial year ended December 31, 2024 (collectively, the "Annual Filings").

SAN FRANCISCO, June 25, 2025 (GLOBE NEWSWIRE) -- Biotechnology firm Iovance Biotherapeutics Inc. (NASDAQ: IOVA) announced a significant leadership transition, confirming the resignation of Chief Financial Officer Jean-Marc Bellemin, effective July 10, 2025. Mr. Bellemin, who assumed the CFO role in November 2020, is reportedly departing to pursue other endeavors, according to a regulatory filing. Bellemin’s exit comes at a tumultuous time, as the company is grappling with a recent commercial setback for its flagship drug, Amtagvi, and the specter of a class-action securities lawsuit.

TORONTO, June 25, 2025 (GLOBE NEWSWIRE) -- Kursat Kacira, the Chairman and President (the “Acquiror”) of Altai Resources Inc. (“Altai” or the “Company”), announced today that he has acquired a direct ownership of 373,843 common shares of the Company (the “Acquisition”), representing approximately 0.7% of the total issued and outstanding shares of the Company (the “Shares”). Prior to the Acquisition, the Acquiror directly owned 9,726,157 Shares, representing approximately 17.4% of the total issued and outstanding Shares, and indirectly owned 1,000,000 Shares, representing approximately 1.8% of the total issued and outstanding Shares. After giving effect to the Acquisition, the Acquiror has a combined direct and indirect ownership of 11,100,000 Shares, representing approximately 19.8% of the total issued and outstanding Shares. These shares are held for investment purposes.

DURANGO, Colo., June 25, 2025 (GLOBE NEWSWIRE) -- Rocky Mountain Chocolate Factory, Inc. (Nasdaq: RMCF) (the “Company”, “we”, or “RMCF”), America’s Chocolatier^TM and a leading franchiser of a premium chocolate and confectionary retail store concept, announced that it has regained compliance with Nasdaq Listing Rule 5250(c)(1) following the filing of its Annual Report on Form 10-K for the fiscal year ended February 28, 2025. Nasdaq Listing Rule 5250(c)(1) requires listed companies to file all required annual and quarterly reports with the SEC on a timely basis.

SHENZHEN, CHINA, June 25, 2025 (GLOBE NEWSWIRE) -- The board of directors of China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) announces the proposed secondary listing of the Company’s ordinary shares (“Shares”) on the Singapore Exchange Securities Trading Limited (the “SGX-ST”) by way of introduction (the “Proposed Secondary Listing”). The Proposed Secondary Listing, if proceeded, will not involve issuance of new shares, and the Shares will continue to be primarily listed and traded on the Hong Kong Stock Exchange thereafter.

REYKJAVIK, ICELAND, PISCATAWAY, NEW JERSEY AND LONDON, UK (June 25, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company headquartered in New Jersey, US, and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK-headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines, today announced positive topline results from a confirmatory efficacy study comparing AVT23 (ADL-018), a proposed biosimilar to Xolair® (omalizumab), with the reference biologic.

NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) on behalf of long-term stockholders following a class action complaint that was filed against Maravai on March 3, 2025 with a Class Period from August 7, 2024 and February 24, 2025. Our investigation concerns whether the board of directors of Maravai have breached their fiduciary duties to the company.

Not for distribution to United States news wire services or for dissemination in the United States.

Not for dissemination in the United States of America